Table 2

Summary of patient outcomes

Sarilumab
(n=28)
Comparison group
(n=28)
P value
Clinical improvement, n (%)17 (60)18 (64)0.99
Time to clinical improvement (days)18 (9–28)19 (11–28)0.89
Death, n (%)2 (7)5 (18)0.42
Time to death (days)19 (13–26)4 (3–4) 0.006
Live discharge, n (%)17 (60)17 (60)0.99
Time to discharge (days)12 (8–20)13 (10–20)0.35
Mechanical ventilation, n (%)6 (21)7 (25)0.99
Time to mechanical ventilation (days)5 (1–6)3 (2–4)0.52
Fever resolution, n (%)28 (100)28 (100)0.99
Time to fever resolution (days)1 (1–1)4 (1–4) <0.0001
CRP normalisation, n (%)24 (86)17 (61)0.06
Time to CRP normalisation (days)6 (4–7)12 (9–15) <0.0001
Adverse events
 Infections6 (21)5 (18)0.99
 Neutropenia4 (14)0 (0)0.11
 Increase in liver enzymes4 (14)0 (0)0.11
 Thromboembolism2 (7)2 (7)0.99
  • Categorical data are reported as number of patients (n) and percentage (%). Increase in liver enzymes indicates an increase in serum levels of alanine aminotransferase and aspartate aminotransferase more than three times the upper limit of normal. A p value < 0.05 was considered statistically significant.

  • Bold indicates significant values.

  • CRP, C-reactive protein.